Weekly News Wrap-Uup on Health Care Industry (Europe, North America, Asia/Pacific) showing the latest development of most striking fundamental economic and financial news

1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page1
Focus on Europe
Focus on North America
Focus on Asia Pacific
AstraZeneca s blood thinner Brilinta was no more effective than aspirin at preventing major heart
problems in stroke patients, knocking down its growth ambitions for one of its key drugs. (wsj.com)
Elekta forms an eight year strategic partnership of a value of more than $100 million with
GenesisCare, the largest provider of radiotherapy in Australia. (prnewswire.com)
GlaxoSmithKline is taking action to make medicines more affordable in developing countries,
including ai i g pate t prote tio for e drugs i the orld s poorest atio s. (theguardian.com)
Indivior launched its first o ile tool, the SUBOXONE® Su li gual Fil CIII Mo ile Health Li rary™,
a free app supporti g patie ts treatment with SUBOXONE Film. (prnewswire.com)
Qiagen announced that it is making a bid to acquire Danish life science research tool and molecular
diagnostics firm Exiqon for approximately $103.5 million. (genomeweb.com)
Roche announced that the FDA has provided approval to initiate collection and testing of blood
samples for screening with the cobas® Zika assay under an IND protocol. (streetinsider.com)
Weekly News Wrap-Up: HEALTH CARE Industry
No. 5
2016-04-03
AstraZeneca Biogen Centene Chugai Pharmaceutical Daiichi Sankyo Elekta GlaxoSmithKline
Indivior Medtronic Qiagen Roche Takeda Pharmaceutical Thermo Fisher Scientific Vertex
SPOTLIGHT
COMPANY NEWS
Biogen received a positive opinion for the marketing authorization of FLIXABI®, an infliximab
biosimilar candidate referencing Remicade®i. (streetinsider.com)
Centene has finalized its merger with Health Net, while two other major insurer mergers still await
regulatory approval. (fiercehealthpayer.com)
Medtronic announced that the FDA cleared PillCam(TM) COLON 2 capsule, a new non-invasive
diagnostic test for the evaluation of polyps, for an expanded indication for use. (nasdaq.com)
Thermo Fisher Scientific and Affymetrix Inc. announced that Thermo Fisher has completed its
previously announced acquisition of Affymetrix for approximately $1.3 billion. (businesswire.com)
Vertex Pharma s pate t appli atio for its ysti fi rosis therapy Orka i has ee refused y the
Indian Patent Office which argued that the drug is not novel. (pmlive.com)
Chugai Pharmaceutical has won a lawsuit against companies who must now stop manufacturing and
marketing their generic drugs referring to Oxarol Ointment 25mcg/g. (pharmabiz.com)
Daiichi Sankyo announced that Phase 3 clinical trials for AMG 162 (denosumab), a gene recombinant
drug for patients with rheumatoid arthritis, has achieved a major objective. (pipelinereview.com)
Takeda Pharmaceutical and Teva Pharmaceutical Industries Ltd. formed Teva Takeda Yakuhin Ltd. as
a new venture with generics and LLP as core businesses. (businesswire.com)

2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz
Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz
page2
94%
96%
98%
100%
102%
2016-03-29 2016-03-30 2016-03-31 2016-04-01
Europe North America Asia/Pacific
Regional Comparison
Focus on Europe
This week’s stock perfor a ce of the world’s biggest listed health care companies shows a negative
development of -0.4% while their one year change reaches -11.7%. Main driver was the Asian/Pacific
region with -5.7% on a weekly basis and -0.4% on a yearly basis. Europe suffered from a loss of -0.3%
or -17.1% respectively. North America gained +0.3% this week but experienced -10.6% for one year.
Weekly News Wrap-Up: HEALTH CARE Industry
No. 5
2016-04-03
Genmab Hikma Merck Novartis Novo Nordisk
Qiagen Roche Shire Straumann UCB
SPOTLIGHT
FINANCIAL MARKET NEWS
Taki g a look at Europe’s top performer this week, the most striking candidate is Genmab, gaining
+7.8% on a weekly basis while its one year performance culminates in +75.7%. Second winner from
Europe is Qiagen with a gain of +5.7% this week, whereas its one year change amounts to -13.1%.
Regarding the lower end of the weekly performance ranking, Novartis takes the lead due to its
decline of -4.1% compared to its one year change of -32.4%. Next is Novo Nordisk, suffering from a
decrease of -1.5% this week and facing a one year performance of -4.2%.
Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
STOXX® Europe 600
Health Care
688.77 -0.27% -17.14% 697.82 676.78 879.13 654.95
STOXX® North America 600
Health Care
791.64 +0.28% -10.59% 796.23 776.52 966.34 730.68
STOXX® Asia/Pacific 600
Health Care
403.55 -5.71% -0.36% 428.71 402.17 446.92 349.32
STOXX® Global 1800
Health Care
695.56 -0.37% -11.68% 698.45 680.20 842.76 647.94
flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Novartis 62.80 -4.12% -32.35% 65.59 61.33 99.00 61.28
Novo Nordisk 48.29 -1.45% -4.23% 48.49 47.15 55.99 40.85
UCB 67.98 -1.41% -2.77% 68.95 67.15 85.56 60.84
Merck 73.16 -1.40% -30.86% 75.00 71.26 112.44 70.71
Roche 215.87 -0.85% -16.41% 219.72 210.59 279.90 210.45
top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low
Genmab 124.21 +7.82% +75.69% 124.21 112.94 131.38 66.07
Qiagen 20.18 +5.70% -13.05% 20.18 19.17 26.00 17.77
Hikma 1'997.00 +5.43% -6.28% 1'998.00 1'894.00 2'520.00 1'575.00
Shire 51.27 +5.07% -28.46% 51.46 49.67 82.00 43.98
Straumann 309.89 +4.90% +21.00% 309.89 298.36 303.35 233.44